Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

Back to Search
Print
Bookmark Trial

NCT00845273

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Macular Degeneration
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients need to be administered Macugen® in order to be enrolled in the surveillance.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients not administered Macugen®.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Macular DegenerationLong-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
NCT00845273
ALL GENDERS
0+
years
MULTIPLE SITES
Macular DegenerationClinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
NCT00239928
  1. Nagoya, Aichi
  2. Urayasu, Chiba
  3. Fukuoka-shi, Fukuoka-ken
  4. Maebashi, Gunma
  5. Sapporo, Hokkaido
  6. Moriguchi, Osaka
  7. Suita, Osaka
  8. Otsu, Shiga
  9. Chiyoda-ku, Tokyo
  10. Shinjuku-ku, Tokyo
  11. Fukushima,
  12. Kyoto,
ALL GENDERS
51 Years+
years
MULTIPLE SITES
Macular DegenerationEvaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
NCT00324116
  1. Angers, Cedex 09
  2. Lyon, Cedex 4
  3. Besancon, Cedex
  4. Creteil, Cedex
  5. Macon, Cedex
  6. Poitiers, Cedex
  7. Bayonne,
  8. Belfort Cedex,
  9. Bordeaux,
  10. Bordeaux,
  11. Brest,
  12. DIJON Cedex,
  13. La Rochefoucauld,
  14. La Tronche,
  15. Lille,
  16. Limoges Cedex 1,
  17. Lyon,
  18. Marseille,
  19. Montpellier,
  20. Montpellier,
  21. MULHOUSE Cedex 1,
  22. Nancy,
  23. Nantes Cedex 1,
  24. Paris cedex 12,
  25. PARIS Cedex 19,
  26. Paris,
  27. Paris,
  28. Rives,
  29. Rouen,
  30. Saint-Herblain,
  31. Strasbourg Cedex,
  32. Strasbourg,
  33. Toulouse,
  34. Toulouse,
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Macular DegenerationClinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
NCT00150202
  1. Nagoya, Aichi
  2. Urayasu-shi, Chiba-ken
  3. Tokyo, Chiyoda-ku
  4. Fukuoka-shi, Fukuoka-ken
  5. Maebashi, Gunma
  6. Sapporo, Hokkaido
  7. Kida-gun, Kagawa
  8. Moriguchi, Osaka
  9. Suita, Osaka
  10. Otsu, Shiga
  11. Mitaka, Tokyo
  12. Shinjuku-ku, Tokyo
  13. Fukushima,
  14. Kyoto,
ALL GENDERS
50 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
Official Title Special Investigation For Long-term Use Of Macugen (Regulatory Post Marketing Commitment Plan).
Brief Summary The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.
Detailed Description All the patients whom an investigator prescribes the first Macugen® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population The patients whom an investigator involving A5751033 prescribes the Macugen®).
Condition Macular Degeneration
Intervention Drug: Pegaptanib sodium

Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.

Frequency and duration are according to Package Insert as follows. "Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )".

Other Name: Macugen
Study Groups/Cohorts Pegaptanib sodium
Patients administered Pegaptanib sodium.
Intervention: Drug: Pegaptanib sodium
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: August 3, 2015)		3538
Original Estimated Enrollment
 (submitted: February 16, 2009)		1000
Actual Study Completion Date February 2014
Actual Primary Completion Date February 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients need to be administered Macugen® in order to be enrolled in the surveillance.

Exclusion Criteria:

  • Patients not administered Macugen®.
Sex/Gender
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT00845273
Other Study ID Numbers A5751033
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2015